CoLucid Pharmaceuticals Company Profile (NASDAQ:CLCD)

About CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLCD
  • CUSIP: N/A
  • Web: www.colucid.com
Average Prices:
  • 50 Day Moving Avg: $44.95
  • 200 Day Moving Avg: $33.88
  • 52 Week Range: $5.26 - $46.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -25.85
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -83.51%
  • Return on Assets: -70.62%
Debt:
  • Current Ratio: 11.31%
  • Quick Ratio: 11.30%
Misc:
  • Average Volume: 543,728 shs.
  • Beta: 1.51
 
Frequently Asked Questions for CoLucid Pharmaceuticals (NASDAQ:CLCD)

What is CoLucid Pharmaceuticals' stock symbol?

CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."

How were CoLucid Pharmaceuticals' earnings last quarter?

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) announced its earnings results on Wednesday, November, 9th. The company reported ($0.79) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.79). View CoLucid Pharmaceuticals' Earnings History.

Where is CoLucid Pharmaceuticals' stock going? Where will CoLucid Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 12 month price targets for CoLucid Pharmaceuticals' stock. Their predictions range from $40.00 to $57.00. On average, they expect CoLucid Pharmaceuticals' share price to reach $48.10 in the next twelve months. View Analyst Ratings for CoLucid Pharmaceuticals.

What are analysts saying about CoLucid Pharmaceuticals stock?

Here are some recent quotes from research analysts about CoLucid Pharmaceuticals stock:

  • 1. Piper Jaffray Companies analysts commented, "We see this announcement as resulting from CoLucid's clean design and execution of its Phase III program for oral lasmiditan, and expect the second Phase III SPARTAN trial to read out on schedule in 3Q17. On the GLADIATOR open-label study, we believe that retention rates remain at >70% and that Lilly has likely performed thorough diligence on ongoing safety, efficacy, and compliance in the program. Therefore we see relatively low risk to new information arising in the near-term which threatens completion of this transaction. Overall, the bid confirms our long-held thesis around clinical value of a new acute migraine treatment that provides advantages over standard-of-care triptans on CV safety as well as efficacy for some patients. At this time, we are reducing our rating for CLCD to Neutral." (1/18/2017)
  • 2. According to Zacks Investment Research, "CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company's product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts. " (1/10/2017)

Who are some of CoLucid Pharmaceuticals' key competitors?

When did CoLucid Pharmaceuticals IPO?

(CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and William Blair was co-manager.

How do I buy CoLucid Pharmaceuticals stock?

Shares of CoLucid Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CoLucid Pharmaceuticals' stock price today?

One share of CoLucid Pharmaceuticals stock can currently be purchased for approximately $46.53.


MarketBeat Community Rating for CoLucid Pharmaceuticals (NASDAQ CLCD)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $48.10 (3.37% upside)

Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/23/2017Barclays PLCDowngradeOverweight -> Equal Weight$45.00N/AView Rating Details
1/18/2017BTIG ResearchSet Price TargetBuy$52.00N/AView Rating Details
1/18/2017William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
1/18/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$49.00 -> $46.50N/AView Rating Details
10/24/2016Stifel NicolausBoost Price TargetBuy$30.00 -> $40.00N/AView Rating Details
9/19/2016Ladenburg Thalmann Financial ServicesSet Price TargetBuy$57.00N/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Earnings by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Earnings History by Quarter for CoLucid Pharmaceuticals (NASDAQ CLCD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/20169/30/2016($0.79)($0.79)ViewN/AView Earnings Details
8/10/2016Q2($0.84)($1.06)ViewN/AView Earnings Details
5/11/2016Q1($0.73)($0.85)ViewN/AView Earnings Details
3/2/2016Q4 2015($0.64)($0.74)ViewN/AView Earnings Details
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details
8/12/2015Q2 2015($0.40)($1.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Current Year EPS Consensus Estimate: $-3.46 EPS
Next Year EPS Consensus Estimate: $-1.80 EPS

Dividends

Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.17%
Insider Trades by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Institutional Ownership by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Insider Trades by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Linda C HoganInsiderSell2,580$35.18$90,764.40View SEC Filing  
1/5/2017Thomas P MathersCEOSell1,502$34.78$52,239.56View SEC Filing  
1/3/2017Bernice KucaInsiderSell772$36.25$27,985.00View SEC Filing  
1/3/2017Matthew D DallasCFOSell1,473$36.25$53,396.25View SEC Filing  
12/5/2016Linda C HoganInsiderSell2,583$37.77$97,559.91View SEC Filing  
12/5/2016Thomas P. MathersCEOSell1,502$38.75$58,202.50View SEC Filing  
12/1/2016Bernice KucaInsiderSell772$35.22$27,189.84View SEC Filing  
12/1/2016Matthew D. DallasCFOSell1,473$35.17$51,805.41View SEC Filing  
11/7/2016Linda C HoganInsiderSell1,862$28.56$53,178.72View SEC Filing  
11/7/2016Thomas P MathersCEOSell1,502$28.57$42,912.14View SEC Filing  
11/1/2016Linda C HoganInsiderSell719$30.00$21,570.00View SEC Filing  
10/5/2016Linda C HoganInsiderSell2,581$37.22$96,064.82View SEC Filing  
10/5/2016Thomas P MathersCEOSell1,502$37.08$55,694.16View SEC Filing  
9/14/2016Thomas P MathersCEOSell6,000$23.32$139,920.00View SEC Filing  
9/9/2016A/S NovoMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
9/7/2016Thomas P MathersCEOSell6,502$21.72$141,223.44View SEC Filing  
9/6/2016Linda C HoganInsiderSell48,736$19.87$968,384.32View SEC Filing  
8/31/2016Raymond SkwierczynskiInsiderSell150$10.86$1,629.00View SEC Filing  
8/19/2016Raymond SkwierczynskiInsiderSell508$8.41$4,272.28View SEC Filing  
8/10/2016Raymond SkwierczynskiInsiderSell508$8.30$4,216.40View SEC Filing  
8/5/2016Thomas P MathersCEOSell1,502$8.31$12,481.62View SEC Filing  
8/3/2016Domain Partners Vi, L.P.Major ShareholderSell153,028$8.45$1,293,086.60View SEC Filing  
7/29/2016Raymond SkwierczynskiInsiderSell508$9.09$4,617.72View SEC Filing  
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.76View SEC Filing  
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.80View SEC Filing  
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.16View SEC Filing  
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50View SEC Filing  
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Source:
DateHeadline
finance.yahoo.com logoLilly Completes Acquisition of CoLucid Pharmaceuticals
finance.yahoo.com - June 7 at 7:09 PM
News IconAn experimental treatment for migraines just passed a critical study
www.businessinsider.com - May 12 at 9:56 PM
nasdaq.com logo5 Top Technology Investments To Make In 2017
www.nasdaq.com - May 11 at 4:57 PM
americanbankingnews.com logoCoLucid Pharmaceuticals (CLCD) Getting Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 28 at 12:42 PM
americanbankingnews.com logoCoLucid Pharmaceuticals (CLCD) Receives Daily News Impact Score of 0.44
www.americanbankingnews.com - April 18 at 2:20 PM
americanbankingnews.com logoCoLucid Pharmaceuticals Inc (CLCD) Cut to "Equal Weight" at Barclays PLC
www.americanbankingnews.com - April 9 at 3:46 PM
americanbankingnews.com logoCoLucid Pharmaceuticals Inc (CLCD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 12:38 PM
finance.yahoo.com logoAndreas Halvorsen Sells Amazon, MasterCard in 4th Quarter
finance.yahoo.com - March 19 at 11:47 AM
streetinsider.com logoEli Lilly & Co. (LLY) Completes Takeover of CoLucid Pharmaceuticals (CLCD) - StreetInsider.com
www.streetinsider.com - March 1 at 9:24 PM
biz.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delis
biz.yahoo.com - March 1 at 9:24 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
finance.yahoo.com - February 2 at 4:39 PM
uk.finance.yahoo.com logoBragar Eagel & Squire, P.C. Is Investigating the Board …
uk.finance.yahoo.com - January 31 at 9:47 PM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - January 31 at 9:47 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - January 31 at 4:45 PM
businesswire.com logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - January 30 at 10:14 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - January 30 at 10:14 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - January 27 at 5:44 PM
businesswire.com logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - January 23 at 4:37 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - January 23 at 4:37 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - January 23 at 4:37 PM
prnewswire.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM
prnewswire.com logoCOLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM
finance.yahoo.com logoCOLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company
finance.yahoo.com - January 20 at 5:30 PM
prnewswire.com logoCoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release)
www.prnewswire.com - January 19 at 10:35 PM
streetinsider.com logoEli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.com
www.streetinsider.com - January 19 at 10:34 PM
rttnews.com logoCoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger News
www.rttnews.com - January 19 at 5:33 PM

Social

Chart

CoLucid Pharmaceuticals (CLCD) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff